Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
11.16
+0.10 (0.90%)
Mar 12, 2025, 10:28 AM EST - Market open
Oruka Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
417.84M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 0 | - | - |
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 46.86M | 42.97M | 1,105.27% |
Dec 31, 2006 | 3.89M | 3.34M | 613.39% |
Dec 31, 2005 | 545.00K | 350.00K | 179.49% |
Dec 31, 2004 | 195.00K | -829.00K | -80.96% |
Dec 31, 2003 | 1.02M | -24.53M | -95.99% |
Dec 31, 2002 | 25.55M | 964.00K | 3.92% |
Dec 31, 2001 | 24.59M | 8.99M | 57.59% |
Dec 31, 2000 | 15.60M | 9.21M | 143.93% |
Dec 31, 1999 | 6.40M | -3.19M | -33.30% |
Dec 31, 1998 | 9.59M | 3.39M | 54.70% |
Dec 31, 1997 | 6.20M | 5.77M | 1,355.16% |
Dec 31, 1996 | 426.00K | -1.70M | -79.97% |
Dec 31, 1995 | 2.13M | 2.08M | 4,154.00% |
Dec 31, 1994 | 50.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
United Parcel Service | 91.07B |
RTX Corporation | 80.74B |
Lockheed Martin | 71.04B |
The Boeing Company | 66.52B |
Caterpillar | 64.81B |
Deere & Company | 47.86B |
General Electric Company | 38.70B |
Honeywell International | 38.50B |
ORKA News
- 5 days ago - Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 5 days ago - Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 21 days ago - Oruka Therapeutics to Present at Multiple March Investor Conferences - GlobeNewsWire
- 2 months ago - Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody - GlobeNewsWire
- 3 months ago - Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) - GlobeNewsWire
- 4 months ago - Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Oruka Therapeutics to Present at Multiple November Investor Conferences - GlobeNewsWire
- 6 months ago - Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - GlobeNewsWire